Pregabalin for Opioid-resistant Neuropathic Pain in Bone Metastases

Area of Science:

• Oncology
• Pain Management
• Pharmacology

Background:

• Neuropathic pain is a common complication in cancer patients with bone metastases.
• Opioid-resistant pain presents a significant challenge in palliative care.
• Pregabalin is an anticonvulsant medication with analgesic properties.

Purpose of the Study:

• To assess the tolerability and effectiveness of pregabalin for opioid-resistant neuropathic pain in cancer patients with bone metastases.
• To identify factors influencing pregabalin treatment outcomes in this population.

Main Methods:

• Retrospective review of medical records from 26 cancer patients with bone metastases and neuropathic pain.
• Evaluation of pregabalin tolerability based on treatment continuation and adverse events.
• Assessment of pain relief using the numerical rating scale (NRS) over a 7-35-day period, excluding chemotherapy/radiotherapy effects.

Main Results:

• 23% of patients discontinued pregabalin due to adverse events (dizziness, somnolence), primarily those aged 60 years or older.
• 67% of patients who continued treatment showed consistent NRS score reduction, with 33% achieving ≥50% pain intensity reduction.
• Pain relief was observed in 80% of patients even at low pregabalin dosages (50-75 mg/day).

Conclusions:

• Pregabalin shows potential in managing opioid-resistant neuropathic pain associated with bone metastases.
• Tolerability can be an issue, particularly in older patients, highlighting the importance of dose titration.
• Initiating pregabalin at a low dose may improve tolerability and effectiveness in elderly cancer patients.